Optimized generation of survivin-specific cytotoxic T lymphocytes against lung cancer

Li,Ying; Ding,Juanjuan

doi:10.3892/mmr.2015.3579

Optimized generation of survivin-specific cytotoxic T lymphocytes against lung cancer

Authors:
- Ying Li
- Juanjuan Ding
View Affiliations

Affiliations: Department of Respiratory Medicine, Henan Provincial People's Hospital, Zhengzhou, Henan 450003, P.R. China
Published online on: April 1, 2015 https://doi.org/10.3892/mmr.2015.3579
Pages: 2169-2174

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer immunotherapy based on dendritic cells (DCs) that target survivin is a promising strategy with potential clinical applications. However, the translation of survivin‑specific cytotoxic T‑lymphocyte (CTL) immunotherapy into the clinical setting has numerous challenges, including the low efficiency of the treatment. The present study aimed to improve the efficiency of the treatment, and found that treatment with interleukin 4 (IL‑4)/granulocyte macrophage colony‑stimulating factor (GM‑CSF) and a combination of proinflammatory cytokines significantly increased the antigen‑presenting and ‑capture abilities of DCs that expressed exogenous survivin. Furthermore, lipopolysaccharide (LPS) stimulation enhanced the DC response to subsequent T‑cell signals and the extent of T‑cell activation. In addition, the efficiency of survivin‑specific CTLs was examined, and high cytotoxicity against survivin‑expressing A549 lung cancer cells was observed. However, the cytotoxicity of CTLs was significantly reduced in A549 cells with silenced survivin expression. The present study provides a novel method to optimize the generation of survivin‑specific CTLs against lung cancer cells, which may advance the translation of survivin‑specific CTL immunotherapy into clinical use for the treatment of cancer.

View Figures

View References

1	Lewis LD: Cancer therapeutics revisited; novel drugs targeting cell signalling pathways, genome wide association studies and other trials and tribulations. Br J Clin Pharmacol. 76:317–319. 2013. View Article : Google Scholar : PubMed/NCBI
2	Sliwkowski MX and Mellman I: Antibody therapeutics in cancer. Science. 341:1192–1198. 2013. View Article : Google Scholar : PubMed/NCBI
3	Snook AE and Waldman SA: Advances in cancer immunotherapy. Discov Med. 15:120–125. 2013.PubMed/NCBI
4	Workman P, Al-Lazikani B and Clarke PA: Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. Curr Opin Pharmacol. 13:486–496. 2013. View Article : Google Scholar : PubMed/NCBI
5	Waldmann TA: Immunotherapy: past, present and future. Nat Med. 9:269–277. 2003. View Article : Google Scholar : PubMed/NCBI
6	Bonaccorsi I, Pezzino G, Morandi B and Ferlazzo G: Novel perspectives on dendritic cell-based immunotherapy of cancer. Immunol Lett. 155:6–10. 2013. View Article : Google Scholar : PubMed/NCBI
7	Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
8	Rodel F, Hoffmann J, Distel L, et al: Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res. 65:4881–4887. 2005. View Article : Google Scholar : PubMed/NCBI
9	Su L, Wang Y, Xiao M, Lin Y and Yu L: Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 110:484–491. 2010. View Article : Google Scholar : PubMed/NCBI
10	Zhang M, Latham DE, Delaney MA and Chakravarti A: Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene. 24:2474–2482. 2005. View Article : Google Scholar : PubMed/NCBI
11	Uchida H, Tanaka T, Sasaki K, et al: Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther. 10:162–171. 2004. View Article : Google Scholar : PubMed/NCBI
12	Kikkawa K, Fujii R, Kuramoto T, et al: Dendritic cells with transduced survivin gene induce specific cytotoxic T lymphocytes in human urologic cancer cell lines. Urology. 74:222–228. 2009. View Article : Google Scholar : PubMed/NCBI
13	Schmitz M, Diestelkoetter P, Weigle B, et al: Generation of survivin-specific CD8⁺ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res. 60:4845–4849. 2000.PubMed/NCBI
14	Dauer M, Obermaier B, Herten J, et al: Mature dendritic cells derived from human monocytes within 48 h: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol. 170:4069–4076. 2003. View Article : Google Scholar : PubMed/NCBI
15	Xie Z, Chen Y, Li Z, et al: Smad6 promotes neuronal differentiation in the intermediate zone of the dorsal neural tube by inhibition of the Wnt/beta-catenin pathway. Proc Natl Acad Sci USA. 108:12119–12124. 2011. View Article : Google Scholar : PubMed/NCBI
16	Dauer M, Obermaier B, Herten J, et al: Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol. 170:4069–4076. 2003. View Article : Google Scholar : PubMed/NCBI
17	Ziegler-Heitbrock L: The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol. 81:584–592. 2007. View Article : Google Scholar
18	Abdi K, Singh NJ and Matzinger P: Lipopolysaccharide-activated dendritic cells: “exhausted” or alert and waiting? J Immunol. 188:5981–5989. 2012. View Article : Google Scholar : PubMed/NCBI
19	Mukherjee S, Maiti PK and Nandi D: Role of CD80, CD86, and CTLA4 on mouse CD4(+) T lymphocytes in enhancing cell-cycle progression and survival after activation with PMA and ionomycin. J Leukoc Biol. 72:921–931. 2002.PubMed/NCBI
20	O’Neill DW, Adams S and Bhardwaj N: Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood. 104:2235–2246. 2004. View Article : Google Scholar
21	Zhong H, Shurin MR and Han B: Optimizing dendritic cell-based immunotherapy for cancer. Expert Rev Vaccines. 6:333–345. 2007. View Article : Google Scholar : PubMed/NCBI
22	Shurin MR: Preparation of human dendritic cells for tumor vaccination. Method Mol Biol. 215:437–462. 2003.
23	Jeras M, Bergant M and Repnik U: In vitro preparation and functional assessment of human monocyte-derived dendritic cells-potential antigen-specific modulators of in vivo immune responses. Transpl Immunol. 14:231–244. 2005. View Article : Google Scholar : PubMed/NCBI
24	McIlroy D and Gregoire M: Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact. Cancer Immunol Immunother. 52:583–591. 2003. View Article : Google Scholar : PubMed/NCBI
25	Li F, Ambrosini G, Chu EY, et al: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 396:580–584. 1998. View Article : Google Scholar : PubMed/NCBI